Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Neurofibromatosis 1
Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Neurofibromatosis 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gsk1120212 Novartis Pharmaceuticals | Phase 4 | B |
Dabrafenib Novartis Pharmaceuticals | Phase 4 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Evomela Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →